Diplon, Jeffrey .
HRN: 10-41-01 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/15/2023
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
10/15/2023
10/22/2023
PO
10cc
Q8
Infected Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes